



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/516,405	11/30/2004	Wolfgang Demmer	DES: 3568.0099	2828
152	7590 04/19/2006		EXAMINE	
	, VILHAUER, MCCLUN	FERNANDEZ, SUSAN EMILY		
1600 ODS TO 601 SW SECO	OWER OND AVENUE		ART UNIT	PAPER NUMBER
PORTLAND, OR 97204-3157			1651	· · · · · · · · · · · · · · · · · · ·
			DATE MAN ED 04/10/200	

DATE MAILED: 04/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

`	Application No.	Applicant(s)				
Office Action Summer	10/516,405	DEMMER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Susan E. Fernandez	1651				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  136(a). In no event, however, may a reply be tin  will apply and will expire SIX (6) MONTHS from  e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status	·					
1) Responsive to communication(s) filed on		•				
	action is non-final.					
<u> </u>	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
•	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims	,					
4)⊠ Claim(s) <u>1-15</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>1-15</u> are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119		· · · · · · · · · · · · · · · · · · ·				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
a)						
2. Certified copies of the priority documents have been received in Application No						
Copies of the certified copies of the priority documents have been received in Application No      Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
·						
Attachment(s)	_					
1) Notice of References Cited (PTO-892)		4) Interview Summary (PTO-413) Paper No(s)/Mail Date				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date  5) Notice of Informal Patent Application (PTO-1449 or PTO/SB/08)						
Paper No(s)/Mail Date 6) Other:						

## **DETAILED ACTION**

Claims 1-15 are pending.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-10, drawn to a membrane for removing proteases from a fluid.

Group II, claims 11-15, drawn to a device for removing proteases from biological fluids and pharmaceutical solutions.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I and II lack a single common technical feature because Group II requires a housing containing four membrane bodies arranged in series, not recited in Group I. Thus, a reference which anticipates Group I, for example, would not necessarily anticipate Group II. See, e.g. the BIOSIS abstract of Grano et al. (International Journal of Artificial Organs, April 2002, 25(4)), cited in the International Search Report. Moreover, since Grano et al. anticipates claim 1 of Group I, the claims presented for examination lack an invention step. That is, because the reference anticipates Group I (but not the other group), it is clear that the two groups lack a single common technical feature which defines them over the prior art.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as

Page 3

The species are as follows:

to form a single general inventive concept under PCT Rule 13.1.

- (a) the protease inhibitors capable of binding with a metalloprotease recited in claims 5 and 13;
- (b) the protease inhibitors capable of binding with a cysteine protease recited in claims 7 and 13;
- (c) the protease inhibitors capble of binding with a serine protease recited in claims 9 and 13;

Applicant is required, in reply to this action, to elect a single species, from each of (a) through (c) above), to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Thus, a proper election would appear as follows: --

Applicant hereby elects Group I, claims 1-10, with traverse. For the species election, applicant elects, also with traverse, bestatin for species (a), antipain for species (b), and TLCK for species (c).

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: claims 1-4, 6, 8, 10-12, 14, 15.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

As discussed above, the claims lack a single common special technical feature since Grano et al. anticipates claim 1, and since a reference which anticipates Group I, for example, would not necessarily anticipate Group II.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1651

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan E. Fernandez whose telephone number is (571) 272-3444. The examiner can normally be reached on Mon-Fri 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Susan E. Fernandez Assistant Examiner Art Unit 1651

sef

JRANCISCO PRATS
PRIMARY EXAMINER